Drug Profile

SON 3015

Alternative Names: Anti-IL6-F_HAB-AntiTGFβ; SON-3015

Latest Information Update: 17 Jan 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sonnet Biotherapeutics
Developer Sonnet BioTherapeutics Holdings, Inc
Class Antineoplastics; Recombinant fusion proteins
Mechanism of Action Interleukin 6 inhibitors; Transforming growth factor beta inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

17 Jan 2024 Research development is ongoing Cancer-metastases in USA (Parenteral) (Sonnet Biotherapeutics pipeline, January 2024)
28 Nov 2023 No recent reports of development identified for research development in Cancer-metastases in USA (Parenteral)
08 Feb 2022 Sonnet BioTherapeutics plans to initiate in vivo mice studies in the second half of 2022

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com